New therapies hold great promise—and great danger.
The recall is just the latest in a bacterial contamination scare.
Why the NABP says Canada isn't a safe alternative.
Legislators say it will help ease the problem, but the NCPA says it’s just one part of the solution.
The PBM giant is cutting down on the number of opioids new patients can buy.
The settlement is the end of a long legal battle.
A tricky labeling system could be affecting your patients.
After many years of speculation, a number of biosimilar drugs are hitting the U.S. market.
The provided droppers may have been mislabeled.
Patients need more help managing complicated meds than ever—and pharmacists are there to help.